Even though this supplement helps muscles burn more fat and make more energy, it doesn’t help the body use insulin better to control blood sugar in overweight or obese people.
Scientific Claim
Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol does not improve insulin-stimulated glucose disposal or suppress endogenous glucose production in overweight and obese adults, despite enhancing mitochondrial capacity and fat oxidation.
Original Statement
“Finally, EGCG+RES had no effect on insulin-stimulated glucose disposal, suppression of endogenous glucose production, or lipolysis.”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
RCT with hyperinsulinemic-euglycemic clamp is the gold standard for insulin sensitivity. The claim is appropriately stated as 'no effect,' but probability language is preferred due to small sample size (n=38) and abstract-only access.
More Accurate Statement
“Twelve weeks of supplementation with 282 mg/day epigallocatechin-3-gallate and 80 mg/day resveratrol likely has no effect on insulin-stimulated glucose disposal or suppression of endogenous glucose production in overweight and obese adults, despite enhancing mitochondrial capacity and fat oxidation.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether EGCG+RES consistently fails to improve insulin sensitivity across diverse obese populations and dosages.
Whether EGCG+RES consistently fails to improve insulin sensitivity across diverse obese populations and dosages.
What This Would Prove
Whether EGCG+RES consistently fails to improve insulin sensitivity across diverse obese populations and dosages.
Ideal Study Design
A meta-analysis of ≥8 RCTs (n≥150 per trial) in overweight/obese adults (BMI ≥27) comparing EGCG+RES (282+80 mg/d) vs placebo for ≥8 weeks, with primary outcome: insulin sensitivity via hyperinsulinemic-euglycemic clamp with [6,6-(2)H2]-glucose.
Limitation: Cannot identify subgroups that may respond or explain heterogeneity.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of EGCG+RES on insulin sensitivity using the gold-standard clamp method.
Causal effect of EGCG+RES on insulin sensitivity using the gold-standard clamp method.
What This Would Prove
Causal effect of EGCG+RES on insulin sensitivity using the gold-standard clamp method.
Ideal Study Design
A double-blind RCT with 200 overweight/obese adults (BMI 28–35, aged 30–65) randomized to EGCG+RES (282+80 mg/d) or placebo for 12 weeks, with primary endpoint: insulin-stimulated glucose disposal rate (M-value) via hyperinsulinemic-euglycemic clamp with [6,6-(2)H2]-glucose infusion.
Limitation: Does not assess long-term effects on diabetes risk or beta-cell function.
Prospective Cohort StudyLevel 2bWhether lack of insulin sensitivity improvement with EGCG+RES predicts higher risk of type 2 diabetes in obese individuals.
Whether lack of insulin sensitivity improvement with EGCG+RES predicts higher risk of type 2 diabetes in obese individuals.
What This Would Prove
Whether lack of insulin sensitivity improvement with EGCG+RES predicts higher risk of type 2 diabetes in obese individuals.
Ideal Study Design
A 5-year prospective cohort of 500 obese adults taking EGCG+RES (282+80 mg/d) or not, with annual clamp-measured insulin sensitivity and incident type 2 diabetes as endpoint, adjusting for weight change and physical activity.
Limitation: Cannot prove causation due to confounding by adherence and lifestyle.
Animal Model StudyLevel 4Mechanistic reasons why EGCG+RES improves fat oxidation but not insulin signaling in muscle or liver.
Mechanistic reasons why EGCG+RES improves fat oxidation but not insulin signaling in muscle or liver.
What This Would Prove
Mechanistic reasons why EGCG+RES improves fat oxidation but not insulin signaling in muscle or liver.
Ideal Study Design
A study in diet-induced obese mice (C57BL/6) treated with EGCG+RES (equivalent human dose) for 12 weeks, measuring insulin signaling (Akt phosphorylation), glucose uptake in muscle/liver, and mitochondrial function in parallel.
Limitation: Mouse insulin resistance models do not fully replicate human metabolic disease.
Evidence from Studies
Supporting (1)
This study gave overweight people the exact same supplements for 12 weeks and found their body’s ability to use insulin to control blood sugar didn’t improve — just like the claim says. It did find other benefits, like better fat burning, but that’s not what the claim is about.